Osteogenic molecules for clinical applications: Improving the BMP-collagen system

Biological Research

Volumn 46, Issue 4, 2013, Pages 421-429

  Arrabal, Pilar M ^a,b,c   Visser, Rick ^a,b,c   Santos Ruiz, Leonor ^a,b,c   Becerra, José ^a,b,c   Cifuentes, Manuel ^a,b,c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina IBIMA Plataforma Bionand   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

BMPs; Collagen; FGF 2; Growth factors; Osteogenesis; Recombinant proteins; RGD peptide

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COLLAGEN;

ANIMAL; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; PHYSIOLOGY; TISSUE ENGINEERING;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; HUMANS; OSTEOGENESIS; TISSUE ENGINEERING;

EID: 84893507545     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.4067/S0716-97602013000400013     Document Type: Review

References (90)

1. ALT V, DONELL ST, CHHABRA A, BENTLEY A, EICHER A, SCHNETTLER R (2009) A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France. Injury 40(12):1269-75.
2. ANDRADES JA, WU LT, HALL FL, NIMNI ME, BECERRA J (2001) Engineering, expression, and renaturation of a collagen-targeted human bFGF fusion protein. Growth Factors 18:261-275.
3. ANDRESHAK JL, RABIN SI, PATWARDHAN AG, WEZEMAN FH (1997) Tibial segmental defect repair: chondrogenesis and biomechanical strength modulated by basic fibroblast growth factor. Anat Rec 248(2):198-204.
4. BLAND YS, CRITCHLOW MA, ASHHURST DE (1995). Exogenous fibroblast growth factors-1 and-2 do not accelerate fracture healing in the rabbit. Acta Orthop Scand 66(6):543-8.
5. BODEN SD, KANG J, SANDHU H, HELLER JG (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27(23):2662-73.
6. BRADDOCK M, HOUSTON P, CAMPBELL C, ASHCROFT P (2001) Born again bone: tissue engineering for bone repair. News Physiol Sci 16:208-13.
7. BURKUS JK, DORCHAK JD, SANDERS DL (2003) Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 28(4):372-7.
8. CAPLAN AI (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213:341-7.
9. CHEN B, LIN H, WANG J, ZHAO Y, WANG B, ZHAO W, SUN W, DAI J (2007a) Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2. Biomaterials 28(6):1027-35.
10. CHEN B, LIN H, ZHAO Y, WANG B, ZHAO Y, LIU Y, LIU Z, DAI J (2007b) Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. J Biomed Mater Res A 80(2):428-34.
11. CONSTAM DB, ROBERTSON EJ (1999) Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 144(1):139-49.
12. rd (1995) In vivo evaluation of demineralized bone matrix as a bone graft substitute for posterior spinal fusion. Spine 20(8):877-86.
13. CRISAN M, YAP S, CASTEILLA L, CHEN CW, CORSELLI M, PARK TS, ANDRIOLO G, SUN B, ZHENG B, ZHANG L, NOROTTE C, TENG PN, TRAAS J, SCHUGAR R, DEASY BM, BADYLAK S, BUHRING HJ, GIACOBINO JP, LAZZARI L, HUARD J, PÉAULT B (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301-13.
14. CUI Y, HACKENMILLER R, BERG L, JEAN F, NAKAYAMA T, THOMAS G, CHRISTIAN JL (2001) The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev Nov 15(21):2797-802.
15. DA SILVA MEIRELLES L, CAPLAN AI, NARDI NB (2008) In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26(9):2287-99.
16. DELANY AM, CANALIS E (1998) Basic fibroblast growth factor destabilizes osteonectin mRNA in osteoblasts. Am J Physiol 274: C734-40.
17. EINHORN TA, MAJESKA RJ, MOHAIDEEN A, KAGEL EM, BOUXSEIN ML, TUREK TJ, WOZNEY JM (2003) A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J Bone Joint Surg Am 85(8):1425-35.
18. FENG J, MANTESSO A, DE BARI C, NISHIYAMA A, SHARPE PT (2011) Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci USA 108(16):6503-8.
19. FERRIS DM, MOODIE GD, DIMOND PM, GIORANNI CW, EHRLICH MG AND, VALENTINI RF (1999) RGD-coated titanium implants stimulate increased bone formation in vivo. Biomaterials 20(23-24), 2323-31.
20. FRIEDLAENDER GE, PERRY CR, COLE JD, COOK SD, CIERNY G, MUSCHLER GF, ZYCH GA, CALHOUN JH, LAFORTE AJ, YIN S (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83: S151-8.
21. FRIESS W (1998) Collagen--biomaterial for drug delivery. Eur J Pharm Biopharm 45(2):113-36.
22. GARCÍA AJ, REYES CD (2005) Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84(5):407-13.
23. GARRISON KR, DONELL S, RYDER J, SHEMILT I, MUGFORD M, HARVEY I, SONG F (2007) Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 11(30):1-150.
24. GERMANIER Y, TOSATTI S, BROGGINI N, TEXTOR M, BUSER D (2006) Enhanced bone apposition around biofunctionalized sandblasted and acid-etched titanium implant surfaces. A histomorphometric study in miniature pigs. Clin Oral Implants Res 17(3):251-7.
25. GOVENDER S, CSIMMA C, GENANT HK, Valentin-Opran A, AMIT Y, ARBEL R, ET AL (2002) BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84(12):2123-34.
26. GRANJEIRO JM, OLIVEIRA RC, Bustos-Valenzuela JC, SOGAYAR MC, TAGA R (2005) Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res 38(10):1463-73.
27. HAN B, HALL FL, NIMNI ME (1997) Refolding of a recombinant collagentargeted TGFbeta2 fusion protein expressed in Escherichia coli. Protein Expr Purif 11(2):169-78.
28. HAN B, PERELMAN N, TANG B, HALL F, SHORS EC, NIMNI ME (2002) Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J Orthop Res 20(4):747-55.
29. HOGAN BL (1996) Bone morphogenetic proteins in development. Curr Opin Genet Dev 6(4):432-8
30. HOLLINGER JO, ULUDAG H, WINN SR (1998) Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv Drug Deliv Rev 31(3):303-318.
31. HUBBELL JA (1995) Biomaterials in tissue engineering. Biotechnology 13(6):565-76.
32. Hughes-Fulford M, LI CF (2011) The role of FGF-2 and BMP-2 in regulation of gene induction, cell proliferation and mineralization. J Orthop Surg Res 6(1):8.
33. HURLEY MM, ABREU C, HARRISON JR, LICHTLER AC, RAISZ LG, KREAM BE (2003) Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J Biol Chem 268(8):5588-93.
34. ISHIKAWA T, TERAI H, KITAJIMA T (2001) Production of a biologically active epidermal growth factor fusion protein with high collagen affinity. J Biochem 129(4):627-33.
35. IWAMOTO M, SHIMAZU A, PACIFICI M (1995) Regulation of chondrocyte maturation by fibroblast growth factor-2 and parathyroid hormone. J Orthop Res 13(6):838-45.
36. KATO Y, IWAMOTO M (1990) Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation. J Biol Chem 265(10):5903-9.
37. KAWASE Y, OHDATE Y, SHIMOJO T, TAGUCHI Y, KIMIZUKA F, KATO I (1992) Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin. FEBS Lett 298(2-3):126-8.
38. KEMPEN DH, LU L, HEIJINK A, HEFFERAN TE, CREEMERS LB, MARAN A, YASZEMSKI MJ, DHERT WJ (2009) Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 30(14):2816-25.
39. KITAJIMA T, TERAI H, ITO Y (2007) A fusion protein of hepatocyte growth factor for immobilization to collagen. Biomaterials 28(11):1989-97.
40. KNESER U, SCHAEFER DJ, POLYKANDRIOTIS E, HORCH RE (2006) Tissue engineering of bone: the reconstructive surgeon's point of view. J Cell Mol Med 10(1):7-19.
41. LAUZON MA, BERGERON E, MARCOS B, FAUCHEUX N (2012) Bone repair: new developments in growth factor delivery systems and their mathematical modeling. J Control Release 162(3):502-20.
42. LONG S, TRUONG L, BENNETT K, PHILLIPS A, Wong-Staal F, MA H (2006) Expression, purification and renaturation of bone morphogenetic protein-2 from Escherichia coli. Prot Expr Purif 46(2):374-8.
43. LU M, RABIE AB (2002) The effect of demineralized intramembranous bone matrix and basic fibroblast growth factor on the healing of allogeneic intramembranous bone grafts in the rabbit. Arch Oral Biol 47(12):831-41.
44. MCDONALD NQ, HENDRICKSON WA (1993) A structural superfamily of growth factors containing a cystine knot motif. Cell 73(3):421-4.
45. MIYAZAKI M, ZUK PA, ZOU J, YOON SH, WEI F, MORISHITA Y, SINTUU C, WANG JC (2008) Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine 33(8):863-9.
46. MONTEIRO GA, FERNANDES AV, Sundararaghavan HG and Shreiber DI (2011) Positively and negatively modulating cell adhesion to type I collagen via peptide grafting. Tissue Eng Part A 17(13-14): 1663-73.
47. MOORE NM, LIN NJ, GALLANT ND, BECKER ML (2011) Synergistic enhancement of human bone marrow stromal cell proliferation and osteogenic differentiation on BMP-2-derived and RGD peptide concentration gradients. Acta Biomater 7(5):2091-100.
48. NAGAI H, TSUKUDA R, MAYAHARA H (1995) Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16(3):367-73.
49. NAKASE T, YOSHIKAWA H (2006) Potential roles of bone morphogenetic proteins (BMPs) in skeletal repair and regeneration. J Bone Miner Metab 24(6):425-33.
50. NISHI N, MATSUSHITA O, YUUBE K, MIYANAKA H, OKABE A, WADA F (1998) Collagen binding growth factors: production and characterization of functional fusion proteins having a collagen-binding domain. Proc Natl Acad Sci USA 95(12):7018-23.
51. Nombela-Arrieta C, RITZ J, SILBERSTEIN LE (2011) The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 12(2):126-31.
52. ONG KL, VILLARRAGA ML, LAU E, CARREON LY, KURTZ SM, GLASSMAN SD (2010) Off-Label Use of Bone Morphogenetic Proteins in the United States Using Administrative Data. Spine 35(19):1794-800.
53. OYA K, TANAKA Y, SAITO H, KURASHIMA K, NOGI K, TSUTSUMI H, TSUTSUMI Y, DOI H, Nomura N and HANAWA T (2009) Calcification by MC3T3-E1 cells on RGD peptide immobilized on titanium through electrodeposited PEG. Biomaterials 30(7): 1281-6.
54. PARK JS, YANG HN, JEON SY, WOO DG, NA K, PARK KH (2010) Osteogenic differentiation of human mesenchymal stem cells using RGD-modified BMP-2 coated microspheres. Biomaterials 31(24):6239-48.
55. PECINA M, GILTAIJ LR, VUKICEVIC S (2001) Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 25(4):203-8.
56. PECINA M, HASPL M, JELIC M, VUKICEVIC S (2003) Repair of a resistant tibial non-union with a recombinant bone morphogenetic protein-7 (rh-BMP-7). Int Orthop 27(5):320-1.
57. PEEL SA, HU ZM, CLOKIE CM (2003) In search of the ideal bone morphogenetic protein delivery system: in vitro studies on demineralized bone matrix, purified, and recombinant bone morphogenetic protein. J Craniofac Surg 14(3):284-91.
58. PETRIE TA, RAYNOR JE, REYES CD, BURNS KL, COLLARD DM, GARCÍA AJ (2008) The effect of integrin-specific bioactive coatings on tissue healing and implant osseointegration. Biomaterials 29(19):2849-57.
59. POWER RA, IWANIEC UT, MAGEE KA, Mitova-Caneva NG, WRONSKI TJ (2004) Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos Int 15(9):716-23.
60. REDDI AH (1998) Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 16:247-52.
61. RENGACHARY SS (2002) Bone morphogenetic proteins: basic concepts. Neurosurg Focus 13(6):e2.
62. RODAN SB, WESOLOWSKI G, YOON K, RODAN GA (1989) Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells. J Biol Chem 264(33):19934-41.
63. ROESSLER S, BORN R, SCHARNWEBER D, WORCH H, SEWING A and DARD M (2001) Biomimetic coatings functionalized with adhesion peptides for dental implants. J Mater Sci Mater Med 12(10-12), 871-7.
64. RUPPERT R, HOFFMANN E, SEBALD W (1996) Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237(1):295-302.
65. SAKANO S, HASEGAWA Y, MURATA Y, ITO T, GENDA E, IWATA H, ISHIGURO N, SEO H (2002) Inhibitory effect of bFGF on endochondral heterotopic ossification. Biochem Biophys Res Commun 293(2):680-5.
66. SAREMBA S, NICKEL J, SEHER A, KOTZSCH A, SEBALD W, MUELLER TD (2008) Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 275(1):172-83.
67. SCHMOEKEL HG, WEBER FE, SCHENSE JC, GRATZ KW, SCHAWALDER P, HUBBELL JA (2005) Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 89(3):253-62.
68. SENGLE G, CHARBONNEAU NL, ONO RN, SASAKI T, ALVAREZ J, KEENE DR, BÄCHINGER HP, SAKAI LY. (2008) Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 283(20):13874-88.
69. SONG DP, CHEN MJ, LIANG YC, BAI QS, CHEN JX and ZHENG XF (2010) Adsorption of tripeptide RGD on rutile TiO(2) nanotopography surface in aqueous solution. Acta Biomater 6(2), 684-94.
70. STREET J, BAO M, DEGUZMAN L, BUNTING S, PEALE FV JR, FERRARA N, ET AL (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99(15):9656-61.
71. SWIONTKOWSKI MF, ARO HT, DONELL S, ESTERHAI JL, GOULET J, JONES A, KREGOR PJ, NORDSLETTEN L, PAIEMENT G, PATEL A. (2006) Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88(6):1258-65.
72. TAKAGI J, ASAI H, SAITO Y (1992) A collagen/gelatin-binding decapeptide derived from bovine propolypeptide of von Willebrand factor. Biochemistry 31(36):8530-4.
73. TUAN TL, CHEUNG DT, WU LT, YEE A, GABRIEL S, HAN B, MORTON L, NIMNI ME, HALL FL (1996) Engineering, expression and renaturation of targeted TGF-beta fusion proteins. Connect Tissue Res 34(1):1-9.
74. ULUDAG H, GAO T, PORTER TJ, FRIESS W, WOZNEY JM (2001) Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am 83:S128-35.
75. VACCARO AR, ANDERSON DG, TOTH CA (2002) Recombinant human osteogenic protein-1 (bone morphogenetic protein-7) as an osteoinductive agent in spinal fusion. Spine 27(16):S59-65.
76. VACCARO AR, PATEL T, FISCHGRUND J, ANDERSON DG, TRUUMEES E, HERKOWITZ HN, PHILLIPS F, HILIBRAND A, ALBERT TJ, WETZEL T, MCCULLOCH JA (2004) A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine 29(17):1885-92.
77. Valentin-Opran A, WOZNEY J, CSIMMA C, LILLY L, RIEDEL GE (2002) Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res (395):110-20.
78. VALLEJO LF, BROKELMANN M, MARTEN S, TRAPPE S, Cabrera-Crespo J, HOFFMANN A, GROSS G, WEICH HA, RINAS U (2002) Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. J Biotechnol 94(2):185-94.
79. VISSER R (2009) Production of collagen-targeted recombinant human growth factor for regenerative medicine purposes: BMP-6 and bFGF. Malaga. Servicio de Publicaciones de la Universidad de Malaga.
80. VISSER R, ARRABAL PM, BECERRA J, RINAS U, CIFUENTES M (2009) The effect of an rhBMP-2 absorbable collagen sponge-targeted system on bone formation in vivo. Biomaterials 30(11):2032-7.
81. VISSER R, ARRABAL PM, Santos-Ruiz L, BECERRA J, CIFUENTES M (2012) Basic fibroblast growth factor enhances the osteogenic differentiation induced by Bone morphogenetic protein-6 in vitro and in vivo. Cytokine 58:27-33.
82. VISSER R, ARRABAL PM, Santos-Ruiz L, Fernández-Barranco R, BECERRA J, CIFUENTES M (2013) A collagen-targeted RGD biomimetic peptide to enhance osteogenesis. Tissue Eng Part A (in press) doi:10.1089/ten.TEA.2012.0610.
83. VUKICEVIK S, GRGUREVIC L (2009) BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev 20(5-6):441-8.
84. WANG JS, ASPENBERG P (1996) Basic fibroblast growth factor enhances bone-graft incorporation: dose and time dependence in rats. J Orthop Res 14(2):316-23.
85. WOO BH, FINK BF, PAGE R, SCHRIER JA, JO YW, JIANG G, DELUCA M, VASCONEZ HC, DELUCA PP (2001) Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 18(12):1747-53.
86. WOZNEY JM, ROSEN V, BYRNE M, CELESTE AJ, MOUTSATSOS I, WANG EA (1990) Growth factors influencing bone development. J Cell Sci 13:149-56.
87. YOUNG S, PATEL ZS, KRETLOW JD, MURPHY MB, MOUNTZIARIS PM, BAGGETT LS, UEDA H, TABATA Y, JANSEN JA, WONG M, MIKOS AG (2009) Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A 15(9):2347-62.
88. ZELLIN G, LINDE A (2000) Effects of recombinant human fibroblast growth factor-2 on osteogenic cell populations during orthopic osteogenesis in vivo. Bone 26(2):161-8.
89. ZHANG L, HUM M, WANG M, LI Y, CHEN H, CHU C and JIANG H (2005) Evaluation of modifying collagen matrix with RGD peptide through periodate oxidation. J Biomed Mater Res A 73(4), 468-75.
90. ZHAO W, HAN Q, LIN H, GAO Y, SUN W, ZHAO Y, WANG B, CHEN B, XIAO Z, DAI J (2008) Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J Mol Med 86(10):1127-38.